Independent UK medicine guidance
How long do Mounjaro side effects last?
There is no exact length of time that Mounjaro side effects last. It depends on the symptom, dose, individual and whether you have recently started treatment or increased your dose. Digestive effects are most commonly reported during dose escalation and generally decrease over time.
Why can symptoms last beyond injection day?
Tirzepatide has a half-life of approximately five days. This supports once-weekly dosing but also means the medicine does not disappear from the body the day after an injection.
This does not provide an exact countdown for side effects. Symptoms can be affected by meals, hydration, constipation, other medicines and underlying health conditions.
Starting and increasing the dose
The licensed starting dose is 2.5mg once weekly for four weeks, followed by 5mg. Further increases are made in 2.5mg steps, with at least four weeks at each dose.
Keep a simple record
- Injection date and dose
- When symptoms begin
- How long they last
- Food and fluid intake
- Vomiting, diarrhoea or constipation
- Any other medicines taken
- Whether symptoms return after each dose
A record helps your prescriber tell a predictable treatment pattern apart from another health problem.
Do not wait for serious symptoms to settle
Seek urgent help for: severe, persistent abdominal pain; repeated vomiting or inability to keep fluids down; signs of significant dehydration; breathing difficulty or swelling of the tongue or throat (call 999); yellowing of the skin or eyes; fainting or confusion; blood in vomit or black stools; severe abdominal swelling with an inability to pass poo or wind.
Mild side effects often improve. Serious symptoms require assessment, not patience.
Common questions
How long do Mounjaro side effects last?
There is no exact length of time. It depends on the symptom, dose, individual and whether you have recently started treatment or increased your dose. Digestive effects such as nausea, vomiting and diarrhoea are most commonly reported during dose escalation and generally decrease over time. Some people feel better within a few days. Others need several weeks to adjust to a dose.
Do the published frequencies apply to me?
Only if they come from the right patient group. The UK patient leaflet reports side-effect frequencies separately depending on why tirzepatide was prescribed and which patients were studied, and the version revised in August 2026 added a set of figures from a type 2 diabetes cardiovascular disease study. Vomiting, stomach pain and constipation, for example, are very common in weight management but common in adults treated for type 2 diabetes. If you are taking Mounjaro for weight loss, use the weight-management figures. Our symptom map sets out which band applies to which group.
Why do side effects last beyond injection day?
Tirzepatide has a half-life of approximately five days. This supports once-weekly dosing but also means the medicine does not disappear from the body the day after an injection. It does not provide an exact countdown, as symptoms can also be affected by meals, hydration, constipation, other medicines and underlying health conditions.
Do I have to increase my dose every four weeks?
Four weeks is a minimum interval, not a requirement to increase every month. If side effects remain troublesome, tell your prescriber before moving up. A lower tolerated dose may be more appropriate than repeatedly increasing into symptoms.
Related guides
Sources: Mounjaro Summary of Product Characteristics (eMC) • Mounjaro Patient Information Leaflet (eMC) • Cambridge University Hospitals tirzepatide guidance
Related reading: side effects usually settle, and progress shows up in more places than the scale. See our guide to non-scale victories on Mounjaro.
Explore other side effects
Tap a point on the body to jump to that symptom, or choose from the full list below. The pink marker shows where you are now.
© 2026 Medstack Ltd. Written and published by Monj (monj.co.uk). You are welcome to link to this page or quote a short extract with a credit and a link. Republishing the text, page structure, safety-routing design or price data, in whole or in part, including to train or ground an automated system, is not permitted without written permission. See our independence statement and editorial and review policy.
Sources referenced on this page
Linked from the text above:
- Mounjaro Summary of Product Characteristics (eMC) www.medicines.org.uk
- Mounjaro Patient Information Leaflet (eMC) www.medicines.org.uk
- Cambridge University Hospitals tirzepatide guidance www.cuh.nhs.uk
Standing primary references for every Monj page:
- Mounjaro (tirzepatide) Summary of Product Characteristics and Patient Information Leaflet, electronic medicines compendium
- MHRA Drug Safety Update: GLP-1 receptor agonists
- NICE TA1026: tirzepatide for managing overweight and obesity
- General Pharmaceutical Council register of pharmacies
- MHRA Yellow Card scheme
